Released on = February 1, 2006, 4:20 am

Press Release Author = Visiongain

Industry = Pharmaceuticals

Press Release Summary = San Francisco, CA and London, UK; 11 January 2006: The
purpose of this visiongain report is to examine the prospects of the world
gastrointestinal market. The gastrointestinal (GI) disorders market is one of the
largest and most important in the pharmaceutical industry, generating revenues of
over $16 billion in 2004. Report author Dr Gordon Low said: \" the gastrointestinal
market is large and fragmented, but with continued opportunities for high revenue
generation, despite increasing commercial pressures.\"

Press Release Body = In 2004, seven GI drugs achieved blockbuster revenues, with the
dominant class being the proton pump inhibitors. Visiongain concludes that the GI
market is going through a period of transition, with generic competition and OTC
switching having a profound effect on the market. By 2011, total revenues for the
leading GI drugs are likely to have declined to approximately $11 billion worldwide.

Clearly, the GI market is facing great challenges in terms of internal competition
and patent expiration, with a mounting generic threat. There are also unmet needs
that provide commercial opportunities. This visiongain report examines the GI market
critically through a comprehensive review of available information, including that
from commercial databases, consultation with the industry, company reports,
business/industry news and consultation with international experts on GI disorders.
Visiongain applied techniques such as financial forecasting, SWOT analysis and the
assessment of unmet needs to provide a comprehensive market report with detailed
analyses and informed opinion.

In particular, this visiongain report concentrates on revenue trends in the world
gastrointestinal market between 2005-2011, patent expiry and generic substitution,
an assessment of prescription-to-OTC switching and lifecycle management strategies.
Furthermore, the report covers pipeline products, with an analysis of the prospects
for these agents.

ENDS
Notes for editors:
To receive your complimentary overview of this report please send an email to Sara
Peerun sara.peerun@visiongain.com, telephone Sara on +44 (0) 20 8767 6711 or visit
the media section on
http://www.visiongainintelligence.com/reportDetail.aspx?reportId

Web Site = http://www.visiongainintelligence.com

Contact Details = Visiongain
40, Tooting High Street
London SW17 0RG

http://www.visiongain.com
sara.peerun@visiongain.com

+44 (0)20 8767 6711
+44 (0)20 8767 5001